Andris H Ellims1, Leah M Iles1, Liang-han Ling1, Belinda Chong2, Ivan Macciocca2, Glenn S Slavin3, James L Hare1, David M Kaye1, Silvana F Marasco4, Catriona A McLean5, Paul A James2, Desirée du Sart2, Andrew J Taylor6. 1. Heart Centre, Alfred Hospital, Melbourne, Australia Baker IDI Heart and Diabetes Institute, Melbourne, Australia. 2. Victorian Clinical Genetics Services, Murdoch Childrens Research Institute, Melbourne, Australia. 3. GE Healthcare, Bethesda, USA. 4. Cardiothoracic Surgery Unit, Alfred Hospital, Melbourne, Australia. 5. Department of Anatomical Pathology, Alfred Hospital, Melbourne, Australia. 6. Heart Centre, Alfred Hospital, Melbourne, Australia Baker IDI Heart and Diabetes Institute, Melbourne, Australia andrew.taylor@bakeridi.edu.au.
Abstract
AIMS: In hypertrophic cardiomyopathy (HCM), attempts to associate genotype with phenotype have largely been unsuccessful. More recently, cardiac magnetic resonance (CMR) imaging has enhanced myocardial fibrosis characterization, while next-generation sequencing (NGS) can identify pathogenic HCM mutations. We used CMR and NGS to explore the link between genotype and fibrotic phenotype in HCM. METHODS AND RESULTS: One hundred and thirty-nine patients with HCM and 25 healthy controls underwent CMR to quantify regional myocardial fibrosis with late gadolinium enhancement (LGE) and diffuse myocardial fibrosis with post-contrast T1 mapping. Collagen content of myectomy specimens from nine HCM patients was determined. Fifty-six HCM patients underwent NGS for 65 cardiomyopathy genes, including 36 HCM-associated genes. Post-contrast myocardial T1 time correlated histologically with myocardial collagen content (r = -0.70, P = 0.03). Compared with controls, HCM patients had more LGE (4.6 ± 6.1 vs. 0%, P < 0.001) and lower post-contrast T1 time (483 ± 83 vs. 545 ± 49 ms, P < 0.001). LGE negatively correlated with left-ventricular (LV) ejection fraction and outflow tract obstruction, whereas lower post-contrast T1 time, suggestive of more diffuse myocardial fibrosis, was associated with LV diastolic impairment and dyspnoea. Patients with identifiable HCM mutations had more LGE (7.9 ± 8.6 vs. 3.1 ± 4.3%, P = 0.03), but higher post-contrast T1 time (498 ± 81 vs. 451 ± 70 ms, P = 0.03) than patients without. CONCLUSION: In HCM, contrast-enhanced CMR with T1 mapping can non-invasively evaluate regional and diffuse patterns of myocardial fibrosis. These patterns of fibrosis occur independently of each other and exhibit distinct clinical associations. HCM patients with recognized genetic mutations have significantly more regional, but less diffuse myocardial fibrosis than those without. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: In hypertrophic cardiomyopathy (HCM), attempts to associate genotype with phenotype have largely been unsuccessful. More recently, cardiac magnetic resonance (CMR) imaging has enhanced myocardial fibrosis characterization, while next-generation sequencing (NGS) can identify pathogenic HCM mutations. We used CMR and NGS to explore the link between genotype and fibrotic phenotype in HCM. METHODS AND RESULTS: One hundred and thirty-nine patients with HCM and 25 healthy controls underwent CMR to quantify regional myocardial fibrosis with late gadolinium enhancement (LGE) and diffuse myocardial fibrosis with post-contrast T1 mapping. Collagen content of myectomy specimens from nine HCM patients was determined. Fifty-six HCM patients underwent NGS for 65 cardiomyopathy genes, including 36 HCM-associated genes. Post-contrast myocardial T1 time correlated histologically with myocardial collagen content (r = -0.70, P = 0.03). Compared with controls, HCM patients had more LGE (4.6 ± 6.1 vs. 0%, P < 0.001) and lower post-contrast T1 time (483 ± 83 vs. 545 ± 49 ms, P < 0.001). LGE negatively correlated with left-ventricular (LV) ejection fraction and outflow tract obstruction, whereas lower post-contrast T1 time, suggestive of more diffuse myocardial fibrosis, was associated with LV diastolic impairment and dyspnoea. Patients with identifiable HCM mutations had more LGE (7.9 ± 8.6 vs. 3.1 ± 4.3%, P = 0.03), but higher post-contrast T1 time (498 ± 81 vs. 451 ± 70 ms, P = 0.03) than patients without. CONCLUSION: In HCM, contrast-enhanced CMR with T1 mapping can non-invasively evaluate regional and diffuse patterns of myocardial fibrosis. These patterns of fibrosis occur independently of each other and exhibit distinct clinical associations. HCM patients with recognized genetic mutations have significantly more regional, but less diffuse myocardial fibrosis than those without. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Dimitrios Maragiannis; Paulino A Alvarez; Mohamad G Ghosn; Karen Chin; Jeremy J Hinojosa; John M Buergler; Dipan J Shah; Sherif F Nagueh Journal: Int J Cardiovasc Imaging Date: 2017-07-26 Impact factor: 2.357
Authors: Bharath Ambale-Venkatesh; Chia-Ying Liu; Yuan-Chang Liu; Sirisha Donekal; Yoshiaki Ohyama; Ravi K Sharma; Colin O Wu; Wendy S Post; Gregory W Hundley; David A Bluemke; João A C Lima Journal: Eur Heart J Cardiovasc Imaging Date: 2019-02-01 Impact factor: 6.875
Authors: Pim van Ooij; Bradley D Allen; Carla Contaldi; Julio Garcia; Jeremy Collins; James Carr; Lubna Choudhury; Robert O Bonow; Alex J Barker; Michael Markl Journal: J Magn Reson Imaging Date: 2015-07-31 Impact factor: 4.813